The prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas

References

• Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676–682.
   PubMed Web of Science ®Google Scholar
• Yuan W, Yumin L, Kehu Y, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010;45(6):665–676.
   PubMed Web of Science ®Google Scholar
• Franceschi F, Tortora A, Gasbarrini G, et al. Helicobacter pylori and extragastric diseases. Helicobacter. 2014;19(Suppl. 1):52–58.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30.
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14.
   PubMed Web of Science ®Google Scholar
• Liu W, Xie Y, Lu H. The fifth national consensus report on the treatment of H. pylori infection. Gastroenterology. 2017;22(6):346–360.
   Google Scholar
• Wang B, Lv ZF, Wang YH, et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014;20(40):14973–14985.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Zhou LY, Song ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21(9):2786–2792.
   PubMed Web of Science ®Google Scholar
• Graham DY, Javed SU, Keihanian S, et al. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol. 2010;45(8):816–820.
   PubMed Web of Science ®Google Scholar
• Yu L, Luo L, Long X, et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter. 2019;24(4):e12596.
   PubMed Web of Science ®Google Scholar
• Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895–905.e5.
   PubMed Web of Science ®Google Scholar
• Gao CP, Xiao X, Liu PX, et al. High-dose amoxicillin/esomeprazole dual therapy as a first-line therapy for H. pylori eradication. World Chin J Digestol. 2018; 26(6):353–359.
   Google Scholar
• Song Z, Zhou L, Xue Y, et al. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25(6):e12762.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang Y, Fan L, et al. Correction: eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114(5):835.
   PubMed Web of Science ®Google Scholar
• Gao CP, Zhang D, Zhang T, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692.
   PubMed Web of Science ®Google Scholar
• Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am. 2010;39(3):465–480.
   PubMed Web of Science ®Google Scholar
• Kamboj S, Gupta GD, Kamboj S, et al. Citric acid as an effective release retarding agent in matrix tablets formulation. World J Eng. 2010;7(Suppl. 3):527–528.
   Google Scholar
• Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81(4):521–528.
   PubMed Web of Science ®Google Scholar
• Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver. 2020;15(5):646–652.
   Web of Science ®Google Scholar
• Lou HY, Chang CC, Sheu MT, et al. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol. 2009;65(1):55–64.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2004;76(4):290–301.
   PubMed Web of Science ®Google Scholar
• Sahara S, Sugimoto M, Uotani T, et al. Potent gastric acid inhibition over 24 hours by 4-times daily dosing of esomeprazole 20 mg. Digestion. 2015;91(4):277–285.
   PubMed Web of Science ®Google Scholar
• Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28(4):448–451.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu YJ, Zhao Z, et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol. 2020;32(5):563–568.
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-H. pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718–1724.
   PubMed Web of Science ®Google Scholar
• Ren L, Lu H, Li HY, et al. New dual therapy for primary treatment of H. pylori infection: a prospective randomized study in Shanghai, China. J Dig Dis. 2014;15(11):622–627.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69(6):1019–1026.
   PubMed Web of Science ®Google Scholar
• Zhou Y. Analysis of 23SrRNA gene mutations associated with drug resistance and clarithromycin resistance of Helicobacter pylori in South Sichuan. Luzhou: Southwest Medical University; 2018.
   Google Scholar
• Ferwana M, Abdulmajeed I, Alhajiahmed A, et al. Accuracy of urea breath test in Helicobacter pylori infection: meta-analysis. World J Gastroenterol. 2015;21(4):1305–1314.
   PubMed Web of Science ®Google Scholar
• Öztürk K, Kurt Ö, Çelebi G, et al. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol. 2020;31(3):234–238.
   PubMed Web of Science ®Google Scholar
• Echizen H. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2016;55(4):409–418.
   PubMed Web of Science ®Google Scholar